SK Biopharmaceuticals signs license deal to introduce its epilepsy med in the Middle East, Africa
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
SK Biopharmaceuticals announced Friday that it had signed an out-licensing deal with Hikma MENA FZE, the Middle East and North Africa unit of British drugmaker Hikma Pharmaceuticals, for its epilepsy medication Cenobamate.
Cenobamate is a medication for partial-onset seizures in adults. The drug is currently sold under the brand name Xcopri in the US and Ontozry in Europe.
Under the agreement, Hikma MENA FZE is granted rights to commercialize Xcopri in 16 countries in the Middle East and North Africa, including Saudi Arabia and Egypt.
“With the latest strategic partnership with Hikma, SK Biopharmaceuticals has secured a bridgehead that will help the company increase its market share in the MENA region,” SK Biopharmaceuticals CEO Lee Dong-hoon said.
According to SK Biopharmaceutical, the anti-epilepsy market in the MENA region is estimated at $442 million.
SK Biopharmaceuticals will also receive an additional upfront payment of $20 million for providing Hikma with priority rights for negotiating over future products launched by SK Biopharmaceuticals in the MENA region.
SK Biopharmaceuticals said the company will reinvest the money from the latest research and development deals for merger and acquisitions.
By Shim Woo-hyun(ws@heraldcorp.com)
Copyright © 코리아헤럴드. 무단전재 및 재배포 금지.